Ultragenyx Pharmaceutical Inc. (RARE) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 49.8 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±10.8% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RARE currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.01) and Max Pain ($17.62) forces dealer call-delta covering toward $41.88.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Ultragenyx Pharmaceutical Inc. (RARE) dropped -2.44% to $16.78, trading at 15% of its 52-week range ($12.73 – $39.89). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Is RARE a good stock to buy? We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on r/ValueInvesting by u/Tallwhitedude123. Since the thesis was published on August 30th, RARE shares have pulled back as a k
https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo (GSK) delivered earnings and revenue surprises of +5.00% and +1.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
For questions about this article or underlying research, email help@trefis.com.
NOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-r
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare stocks fell Monday afternoon with the NYSE Healthcare Index declining 0.6% and the State
On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") and Baylor Research Institute ("BRI") entered into a settlement agreement with Navinta LLC ("Navinta") resolving patent
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RARE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RARE. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Ultragenyx Pharmaceutical Inc. (RARE) ranks #984 by composite RQD confidence (26/100, grade E) and #293 by equity capitalization ($1.65B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with RARE at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RARE
ACTIVE
Ultragenyx Pharmaceutical Inc. | E | 26/100 | — | — | -35.0% | -2.44% | $1.65B | Benchmark Subject |
| URGN UroGen Pharma Ltd. | E | 24/100 | — | 88.7% | -35.0% | -0.80% | $1.64B | /urgn-vs-rare → |
| NUVB Nuvation Bio Inc. (Class A) | E | 29/100 | — | — | -35.0% | +3.92% | $1.67B | /nuvb-vs-rare → |
| ANIP ANI Pharmaceuticals Inc. | B- | 70/100 | 21.5x | — | 16.0% | +2.02% | $1.68B | /anip-vs-rare → |
| CMPS COMPASS Pathways Plc American Depository Shares | D- | 37/100 | — | — | -35.0% | -0.73% | $1.69B | /cmps-vs-rare → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ultragenyx Pharmaceutical Inc. (RARE) reported GAAP revenue of $673.0M (+20.2% vs. FY2024 revenue of $560.0M , and +55.1% cumulative change since FY2023) , GAAP net income of -$575.0M, operating cash flow of -$466.0M, and free cash flow of -$472.0M (-12.1% YoY). On the balance sheet, RARE closed FY2025 with $1.53B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $673.0M | -$575.0M | -$466.0M | -$472.0M | $1.53B | — |
| FY2024 (FY) | 2024-12-31 | $560.0M | -$569.0M | -$414.0M | -$421.0M | $1.50B | — |
| FY2023 (FY) | 2023-12-31 | $434.0M | -$607.0M | -$475.0M | -$475.0M | — | — |
As of 2026-11-01, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $16.78 (-2.44% 1D, market cap $1.65B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RARE ranks #984 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RARE carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, URGN (UroGen Pharma Ltd.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.64B) and NUVB (Nuvation Bio Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
Per RARE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001515673), Ultragenyx Pharmaceutical Inc. generated $673.0M in revenue (+20.2% YoY), -$575.0M in net income, and -$472.0M in free cash flow against $1.53B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RARE last traded at $16.78 (-2.44% on volume of 2,803,830 shares), positioning the stock -1.35% below its 50-day simple moving average ($17.01) and -26.72% below its 200-day simple moving average ($22.90). Across its 52-week range of $12.73 to $39.89, RARE sits at the 14.9% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($14.97 to $18.59).
Why RARE Stock dropped -2.44% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.